TNFSF11 and Miyoshi myopathy: Additional osteoclasts targeting drugs such as: Cyclosporin A (Orcel et al., 1991), Revoremycin A, RANKL antibodies (Ding et al., 2021), Idelalisib (Yeon et al., 2019) and Compactin (Woo et al., 2000) were found to inhibit different satges in osteoclastogenesis and may be usefull to treat MM.